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The “rule of 5” has become a mainstay of decision-making in the pharmaceutical industry as well as in
nonindustrial (academic and institutional) drug development. However the authors of the original paper
never intended for “double cutoffs” to preclude development of new drug leads for parasitic diseases.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).In 1997, Lipinski and co-workers published an article in
Advanced Drug Delivery Reviews entitled “Experimental and
computational approaches to estimate solubility and permeability
in drug discovery and development settings” (Lipinski et al., 1997).
The purpose of the review was to present distinctly different, but
complementary, experimental and computational approaches to
facilitate medicinal chemistry efforts. The major conclusions pre-
sented in this review have become known as “the rule of five”. In
short, the rule of five predicts that poor absorption or drug
permeability is more likely when there are more than 5 H-bond
donors, 10 H-bond acceptors, a molecular weight greater than 500,
and a calculated Log P greater than 5. The term “rule of five” refers
to the fact that each of these conclusions is either 5 or a multiple of
5.
The motivation behind the review was the fact that, in prior
years, the sources of drug leads in the pharmaceutical industry had
changed significantly. Large empirically-based screening programs
became less and less important in the drug industry as the
knowledge base grew for “rational drug design”. With the advent of
combinatorial chemistry, the automated synthesis of massive
numbers of compounds for screening became a reality. This resul-
ted in “HTS” or high throughput screens. The screening of such
large numbers of compounds in turn necessitated a radical depar-
ture from the traditional methods of predicting drug solubility and
permeability. Because drug development became a very expensive
process, it was important that poorly behaving compounds could
be weeded out early. The authors therefore used the United States
Adopted Name (USAN) or International Nonproprietary Name
(INN) to identify compounds that survived.
Having identified a library of drugs selected by the economics ofow).
Ltd on behalf of Australian Society fentry into the Phase II process, the authors identified calculable
parameters for the library that were likely related to absorption or
permeability. The goal was to set up an absorption-permeability
alert procedure to guide medicinal chemists. This is how the au-
thors identified molecular weight, lipophilicity, hydrogen bond
donor groups, and hydrogen bond acceptor groups as predictive
parameters. When they examined the USAN data set, they found
that combinations of any two parameters outside the desirable
range did not exceed 10%.
The “rule of 5” has become a mainstay of decision-making both
within the pharmaceutical industry as well as in nonindustrial drug
screening efforts. However, when drug development efforts began
to focus on new drugs for infectious diseases, and in particular
parasitic diseases, an important question arose as to whether the
“rule of 5” should be applied to Go/No Go decision making. Lipinski
and authors never intended such an application. In fact they stated
in the review “the only orally active compounds outside the double
cutoffs were seven antibiotics. Fungicides-protozoacides also fall
outside the rule”.
It has come to our attention that, despite this stated exception,
many potential anti-parasitic drugs leads have unfortunately been
cast aside, or deprioritized, because they fail two or more “rules”.
This has been the case even if the original hits were discovered in
phenotypic screens versus helminthes or protozoa. This was not the
intent of the original review, nor does it make pharmacological
sense. If the original screen was mechanism-based or biochemical
then of course a confirmatory screen against the parasite itself is
required (Payne et al., 2007; Mugumbate and Overington, 2015).
Even with this cautionary note, as stated in the original review
(Lipinski et al., 1997), several very effective and widely used anti-
biotics fail at least two of the “rules” (Pawlowski et al., 2016).
Given the fact that anti-parasitic drug development is woefully
under-populated and underfunded, we need less stringent, not
more stringent, criteria for advancement. As noted above, lessor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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advanced in a field where there are few leads.Conflict of interest
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